Author + information
Although patients with peripheral arterial disease are at increased risk of cardiovascular morbidity and mortality, evidence based medical therapy (EBMT) is underused in these patients. Prior studies have documented poor adherence to such therapy among patients who have undergone revascularization.
We evaluated the impact of prescription of EBMT prior to discharge after peripheral vascular intervention (PVI) on overall medication compliance in a large multi–specialty, multi–center quality improvement collaborative.
14,105 patients undergoing PVI between 1/1/2008 and 12/31/2011 were included. Post–PVI discharge and six month medication compliance in patients on ASA, beta–blocker (BB) and statin were compared. In addition, clinical outcomes were compared for patients receiving each of the three drugs post–PVI to those that did not.
12,947 (92%) patients were prescribed ASA, 9,788 (69%) BB and 11,609 (82%) statins. Post–procedural use was associated (all p<0.001) with reported six month use: ASA (84.5% vs 39.2%), BB (82.5% vs 11.1%) and statin (84.6% vs 21.8%). No differences in mortality or MI at 6 months was observed.
Prescribing EBMT at the time of PVI is associated with excellent compliance at 6 months, while failure to prescribe EBMT at discharge is associated with low use at 6 months. This data suggest that the time of a PVI is a therapeutic window to prescribe EBMT in this high–risk cohort and represents an opportunity for quality improvement.
Moderated Poster Contributions
Poster Sessions, Expo North
Sunday, March 10, 2013, 3:45 p.m.–4:30 p.m.
Session Title: Arterial Vascular Diseases: Novel Concepts in Diagnosis and Therapy
Abstract Category: 35. Vascular Medicine: Non Coronary Arterial Disease
Presentation Number: 1252M–161
- 2013 American College of Cardiology Foundation